KDMN - Kadmon Holdings, Inc.

NYSE - NYSE Delayed Price. Currency in USD

Kadmon Holdings, Inc.

450 East 29th Street
New York, NY 10016
United States
212-308-6000
http://www.kadmon.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees116

Key Executives

NameTitlePayExercisedYear Born
Dr. Harlan W. WaksalPres, CEO & Director1.08MN/A1953
Mr. Steven MeehanExec. VP & CFO37.5kN/A1965
Mr. Kyle CarverController & Principal Accounting OfficerN/AN/AN/A
Mr. Gregory S. MossEVP, Gen. Counsel, Corp. Sec. & Chief Compliance OfficerN/AN/A1984
Dr. John L. RyanChief Medical Officer & Exec. VPN/AN/A1943
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.

Corporate Governance

Kadmon Holdings, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.